MedPath

Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte

Phase 1
Completed
Conditions
Asthma
Interventions
Drug: Budesonide/formoterol Easyhaler
Drug: Symbicort Turbuhaler
Drug: Charcoal and Budesonide/formoterol Easyhaler
Drug: Charcoal and Symbicort Turbuhaler
Registration Number
NCT01627158
Lead Sponsor
Orion Corporation, Orion Pharma
Brief Summary

The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with the marketed product Symbicort Turbuhaler in terms of the drug absorbed into the bloodstream.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
72
Inclusion Criteria
  1. Written informed consent (IC) obtained.
  2. Males and females, 18-60 (inclusive) years of age.
Read More
Exclusion Criteria
  1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease.
  2. Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of study results or constitute a health risk for the subject if he/she takes part in the study.
  3. Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study.
  4. Known hypersensitivity to the active substance(s) or the excipient of the drug.
  5. Pregnant or lactating females.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Budesonide/formoterol EasyhalerBudesonide/formoterol EasyhalerBudesonide/formoterol Easyhaler
Symbicort TurbuhalerSymbicort TurbuhalerSymbicort Turbuhaler
Charcoal and Budesonide/formoterol EasyhalerCharcoal and Budesonide/formoterol Easyhaler-
Charcoal and Symbicort TurbuhalerCharcoal and Symbicort Turbuhaler-
Primary Outcome Measures
NameTimeMethod
Pharmacokinetic parameter Cmax of plasma budesonide concentrationwithin 12 h
Pharmacokinetic parameter AUCt of plasma budesonide concentration12 h
Pharmacokinetic parameter Cmax of plasma formoterol concentration24 h
Pharmacokinetic parameter AUCt of plasma formoterol concentration24 h
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

PAREXEL International GmbH

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath